PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease
Author:
Affiliation:
1. Department of Pathology and Cell Biology, Columbia University, New York, NY, USA
2. Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY, USA
Publisher
IOS Press
Subject
Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience
Reference42 articles.
1. Cyclic GMP-dependent protein kinase and cellular signaling in the nervous system;Wang;J Neurochem,1997
2. cGMP-induced presynaptic depression and postsynaptic facilitation at glutamatergic synapses in visual cortex;Wei;Brain Res,2002
3. In vivo effects of phosphodiesterase inhibition on basal cyclic guanosine monophosphate levels in the prefrontal cortex, hippocampus and cerebellum of freely moving rats;Marte;J Neurosci Res,2008
4. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use;Bender;Pharmacol Rev,2006
5. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain;Van Staveren;J Comp Neurol,2003
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Sildenafil Reverses the Neuropathological Alzheimer’s Disease Phenotype in Cholinergic-Like Neurons Carrying the Presenilin 1 E280A Mutation;Journal of Alzheimer's Disease;2024-05-14
2. Innovative pathological network‐based multitarget approaches for Alzheimer's disease treatment;Medicinal Research Reviews;2024-04-28
3. Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons;Journal of Alzheimer's Disease;2024-03-19
4. A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer’s disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial;PLOS ONE;2023-10-18
5. PDE5 inhibitor drugs for use in dementia;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3